Substance / Medication

Cefadroxil

Overview

Active Ingredient
cefadroxil
RxNorm CUI
2177

Indications

E. coli P. mirabilis Klebsiella Cefadroxil is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: Urinary tract infections caused by,, andspecies. Skin and skin structure infections caused by staphylococci and/or streptococci. Streptococcus pyogenes Pharyngitis and/or tonsillitis caused by(Group A beta-hemolytic streptococci). Note: Only penicillin by the intramuscular route of administration has been shown t

Labeler: Rebel Distributors CorpUpdated: 2011-01-26T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Cefadroxil is contraindicated in patients with known allergy to the cephalosporin group of antibiotics.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

18 trials linked to this intervention

18
Total Trials
1
Recruiting
4
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Prevention of renal stone disease recurrence. A systematic review of contemporary pharmaceutical options.
Sfoungaristos Stavros, Gofrit Ofer N, Yutkin Vladimir et al. · Expert Opin Pharmacother · 2015
PMID: 25881654Meta-Analysis
Prevalence of scabies and impetigo worldwide: a systematic review.
Romani Lucia, Steer Andrew C, Whitfeld Margot J et al. · Lancet Infect Dis · 2015
PMID: 26088526Meta-Analysis
Interventions for impetigo.
Koning Sander, van der Sande Renske, Verhagen Arianne P et al. · Cochrane Database Syst Rev · 2012
PMID: 22258953Meta-AnalysisFull text (PMC)
Interventions for impetigo.
Koning S, Verhagen A P, van Suijlekom-Smit L W A et al. · Cochrane Database Syst Rev · 2004
PMID: 15106198Meta-Analysis
Strategy to control catheter encrustation with citrated drinks: a randomized crossover study.
Khan Azhar, Housami Fadi, Melotti Roberto et al. · J Urol · 2010
PMID: 20171661RCT
Comparative bioavailability of two cefadroxil products using serum and urine data in healthy human volunteers.
Otoom S, Hasan M, Najib N · Clin Exp Pharmacol Physiol · 2004
PMID: 15236630Trial
Linezolid versus cefadroxil in the treatment of skin and skin structure infections in children.
Wible Kenneth, Tregnaghi Miguel, Bruss Jon et al. · Pediatr Infect Dis J · 2003
PMID: 12690270Trial
Comparison of azithromycin and cefadroxil for the treatment of uncomplicated skin and skin structure infections.
Jennings Maureen B, McCarty James M, Scheffler Neil M et al. · Cutis · 2003
PMID: 14533837Trial
Comparative bioavailability of two cefadroxil formulations in healthy human volunteers after a single-dose administration.
Oliveira C H, Salmon J, Sucupira M et al. · Biopharm Drug Dispos · 2000
PMID: 11304723Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Cefadroxil (substance)
SNOMED CT
372651006
UMLS CUI
C0007538
RxNorm CUI
2177
Labeler
Rebel Distributors Corp

Clinical Data

This intervention maps to 8 entities in the Ltrl knowledge graph.

8
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
18
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.